Public Employees Retirement Association of Colorado Decreases Stock Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Public Employees Retirement Association of Colorado cut its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 0.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 59,624 shares of the medical instruments supplier’s stock after selling 396 shares during the quarter. Public Employees Retirement Association of Colorado owned 0.08% of West Pharmaceutical Services worth $23,594,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Fidelis Capital Partners LLC purchased a new position in shares of West Pharmaceutical Services in the first quarter valued at about $27,000. Quarry LP raised its position in West Pharmaceutical Services by 155.3% during the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 59 shares during the last quarter. Planned Solutions Inc. bought a new position in West Pharmaceutical Services during the 4th quarter valued at approximately $39,000. Hazlett Burt & Watson Inc. purchased a new stake in West Pharmaceutical Services in the 1st quarter worth approximately $40,000. Finally, Northwest Investment Counselors LLC bought a new stake in shares of West Pharmaceutical Services in the 1st quarter worth approximately $40,000. 93.90% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, SVP Silji Abraham sold 1,800 shares of West Pharmaceutical Services stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the sale, the senior vice president now directly owns 2,860 shares in the company, valued at $946,030.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the transaction, the chief executive officer now owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Silji Abraham sold 1,800 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total value of $595,404.00. Following the completion of the sale, the senior vice president now directly owns 2,860 shares in the company, valued at $946,030.80. The disclosure for this sale can be found here. 0.53% of the stock is currently owned by company insiders.

West Pharmaceutical Services Trading Up 1.1 %

Shares of West Pharmaceutical Services stock traded up $3.00 during midday trading on Monday, reaching $287.76. 477,315 shares of the company’s stock traded hands, compared to its average volume of 562,818. The stock has a 50 day moving average of $324.09 and a 200-day moving average of $355.78. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $415.73. The company has a market cap of $20.87 billion, a PE ratio of 37.57, a price-to-earnings-growth ratio of 6.13 and a beta of 1.00. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.68 and a current ratio of 2.34.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The company had revenue of $702.10 million during the quarter, compared to the consensus estimate of $729.36 million. During the same quarter last year, the company posted $2.11 earnings per share. The firm’s revenue for the quarter was down 6.9% compared to the same quarter last year. As a group, equities analysts expect that West Pharmaceutical Services, Inc. will post 6.4 EPS for the current fiscal year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.